Journal
CELL CYCLE
Volume 9, Issue 14, Pages 2769-2776Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.9.14.12268
Keywords
epithelial mesenchymal transition; epidermal growth factor receptor; transforming growth factor alpha
Categories
Funding
- National Institutes of Health [HL086598, HL082818, AI58795, HL90156, HL61646, HL50046]
Ask authors/readers for more resources
Pulmonary fibrosis complicates a number of disease processes and leads to substantial morbidity and mortality. Idiopathic pulmonary fibrosis (IPF) is perhaps the most pernicious and enigmatic form of the greater problem of lung fibrogenesis with a median survival of three years from diagnosis in affected patients. In this review, we will focus on the pathology of IPF as a model of pulmonary fibrotic processes, review possible cellular mechanisms, review current treatment approaches and review two transgenic mouse models of lung fibrosis to provide insight into processes that cause lung fibrosis. We will also summarize the potential utility of signaling pathway inhibitors as a future treatment in pulmonary fibrosis. Finally, we will present data demonstrating a minimal contribution of epithelial-mesenchymal transition in the development of fibrotic lesions in the transforming growth factor-alpha transgenic model of lung fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available